Genedata Screener is the most innovative and powerful HCS solution on the market and the solution’s ability to support phenotypic screening demonstrates how it is continually evolving to meet customer demands
San Francisco, Calif. (PRWEB) January 08, 2013
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it will demonstrate Genedata Screener’s phenotypic screening capabilities at the 10th Annual High Content Analysis (HCA) Conference. Genedata Screener® for High Content Screening (HCS) covers complete screening analysis from cell-level data to final campaign results. Integrating with leading HCS instruments, Genedata Screener simultaneously supports multiple HCS image acquisition and analysis systems while eliminating data analysis bottlenecks and providing instant image access throughout the data analysis pipeline. Genedata Screener for HCS will be demonstrated at the 2013 HCA Conference (Fairmont Hotel; Booth #32) and will be featured in the HCA Technology Showcase on January 9.
Fulfilling the Promise of Phenotypic Screening
While HCS has become routine in drug discovery, the integration of HCS data and images into the data analysis workflow presents challenges. For example, maintaining different instruments and HCS data management systems and deploying separate image analysis solutions consumes time and resources. Additionally, this model often relies on manual workflows with inadequate image access and limitations in throughput or complexity, all of which results in lower productivity and potentially sub-optimal data analysis results. When HCS images are stored in isolated, instrument-specific image data management systems, there is little or no integration with a central-results data warehouse; relevant results are stored without a reference to the original image data.
Genedata Screener for HCS overcomes these workflow challenges. Simultaneously integrating with multiple HCS systems (e.g. PerkinElmer Columbus™ Image Data Management, Thermo Scientific Cellomics® Store database, Molecular Devices MDC Store™ Data Management, openBIS for HCS), Genedata Screener for HCS:
- captures and stores all HCS data analysis images and image analysis results;
- enables interactive definition and analysis of cell populations and the automatic calculation of cell-to-well aggregations;
- unifies HCS data analysis workflow including efficient quality control;
- gives instant access to HCS images all along the data analysis workflow; and
- provides a stand-alone image viewer for downstream applications access to images, even across different geographies.
“With more than a decade of customer experience, best practices, and industry collaboration, Genedata Screener is the most innovative and powerful HCS solution on the market,” said Dr. Othmar Pfannes, CEO of Genedata, “and the solution’s ability to support phenotypic screening demonstrates how it is continually evolving to meet customer demands while advancing the discovery of novel therapies.”
Editorial Note: HCA Technology Showcase – “Get the Big Picture in Phenotypic Screening for Drug Discovery” – January 9, 2013; 2:15pm – 2:45pm. Demonstration of data management workflow from initial capture to result-mining of past experiments.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.